Georgios Geramoutsos

The Effect of Statin Therapy on the Overall Survival of Patients with Hepatocellular Carcinoma: A Single-Center Experience

Konstantinos Papantoniou, Vasileios Lekakis, Efthymios P. Tsounis, Evangelia Bourdalou et autres

Background: Statins have pleiotropic anti-inflammatory, antifibrotic, and potential antineoplastic effects. Although several studies have linked statin exposure to lower hepatocellular carcinoma (HCC) incidence, their effect on survival after HCC diagnosis remains uncertain. We evaluated whether statin therapy before HCC diagnosis was associated …

gr (code pays fourni par la source)

P0531 Steatotic Liver Disease in Inflammatory Bowel Disease: Early Findings from a Prospective Single-Center Cohort.

P Pastras, Maria Antonieta Bali, Konstantinos Papantoniou, Efthymios P. Tsounis et autres

Abstract Background Inflammatory bowel disease (IBD) has been associated with an increased risk of steatotic liver disease (SLD), especially with metabolic dysfunction-associated steatotic liver disease (MASLD). This study assesses the prevalence of SLD and its subtypes in IBD patients and explores their …

gr (code pays fourni par la source)

P0938 Vedolizumab dose intensification: Experience from two Greek tertiary centers.

Pavlos Pardalis, A Ioannou, G Theocharis, Georgios Geramoutsos et autres

Abstract Background Vedolizumab is an established treatment for inflammatory bowel disease (IBD). Loss of response is occasionally encountered. Data regarding dose intensification are limited1. Aim of the study was to evaluate the effectiveness of interval shortening for intravenous vedolizumab (300mg/4 weeks). Methods …

gr (code pays fourni par la source)

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek–Turkish collaborative study

Nikos Viazis, Murat Törüner, Vasilios Papastergiou, Konstantinos Mousourakis et autres

OBJECTIVES: To identify the rate and predictors of successful antitumor necrosis factor (TNF) dose deescalation in patients with inflammatory bowel disease (IBD). METHODS: This multicenter retrospective cohort study collected data from consecutive IBD patients followed at referral centers in Greece and Turkey, …

gr, tr, us, gb (code pays fourni par la source)

High Prevalence and Clinical Associations of Vitamin D Deficiency in Inflammatory Bowel Disease: Evidence from a Tertiary Center Cohort

Theodora Kafentzi, Ploutarchos Pastras, Ioanna Aggeletopoulou, Efthymios P. Tsounis et autres

Background/Objectives: Vitamin D in its active form, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], plays a critical role in immune regulation, gut barrier function, and systemic inflammation. Its deficiency is frequent in Inflammatory Bowel Disease (IBD), but the clinical implications remain uncertain. The aim of the …

gr (code pays fourni par la source)

WED-103 Impact of statin therapy on survival in hepatocellular carcinoma: a single-center study

Konstantinos Papantoniou, Efthymios P. Tsounis, Evangelia Bourdalou, Nikitas Kimiskidis et autres

Vitamin D in Irritable Bowel Syndrome: Exploring Its Role in Symptom Relief and Pathophysiology

Ioanna Aggeletopoulou, Georgios Geramoutsos, Ploutarchos Pastras, Christos K Triantos

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder. Despite its common occurrence, the pathophysiology of IBS remains not fully understood. Emerging evidence suggests that IBS is a multifactorial condition characterized by low-grade inflammation, immune system activation, impaired gut permeability, intestinal …

gr (code pays fourni par la source)

Genetic Polymorphisms (ApaI, FokI, BsmI, and TaqI) of the Vitamin D Receptor (VDR) Influence the Natural History and Phenotype of Crohn’s Disease

Theodora Kafentzi, Efthymios P. Tsounis, Evanthia Tourkochristou, Evdoxia Avramopoulou et autres

Vitamin D receptor (VDR) single-nucleotide polymorphisms (SNPs) modulate vitamin D/VDR signaling, a key pathway in inflammatory bowel disease (IBD) pathogenesis. This study investigates how ApaI, BsmI, TaqI, and FokI SNPs affect IBD phenotype and progression. A total of 76 Crohn’s disease (CD) …

gr (code pays fourni par la source)

P1264 Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with Inflammatory Bowel Disease (IBD). A prospective single-center study

Ploutarchos Pastras, Konstantinos Papantoniou, Efthymios P. Tsounis, Stavros Kanaloupitis et autres

Abstract Background Inflammatory bowel disease (IBD) has been linked to an increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD). This study assesses MASLD prevalence in IBD patients and its associations with demographic, clinical, and laboratory features. Methods This prospective study included …

gr (code pays fourni par la source)

P1308 The ApaI polymorphism in the vitamin D receptor (VDR) gene affects the phenotype and complications of Crohn’s disease

Efthymios P. Tsounis, Theodora Kafentzi, Evanthia Tourkochristou, Evdoxia Avramopoulou et autres

Abstract Background Vitamin D, through its receptor (VDR), exerts pleiotropic effects that support gut barrier homeostasis. Dysregulation of the vitamin D/VDR signaling is implicated in the pathogenesis of inflammatory bowel disease (IBD).1,2 Our study aims to elucidate how the ApaI, BsmI, TaqI, …

gr (code pays fourni par la source)

P1219 Late onset inflammatory bowel disease (IBD): Experience from two tertiary centers in Greece

Adam Ioannou, Georgios J Theocharis, Georgios Geramoutsos, Christos Sotiropoulos et autres

Abstract Background The incidence of IBD in the elderly has increased in recent years1. Aim of the study was the reporting of disease and patient characteristics when IBD diagnosis was set after 60 years. Methods Data were retrieved retrospectively from patients’ medical …

gr (code pays fourni par la source)

P0766 Rate and predictors of successful anti-TNF de-escalation in dose escalated IBD patients. A real-world Greek - Turkish collaborative study

Nikos Viazis, Murat Törüner, V. Papastergiou, K Mousourakis et autres

Abstract Background Anti-TNFa agents (anti-TNFs) are still the first line therapy for patients with Inflammatory Bowel Disease (IBD). We aimed to i) report IBD patients receiving anti-TNFs, who needed dose escalation because of secondary loss of response, and (ii) identify the rate …

gr, tr, us (code pays fourni par la source)